ELA vs MSC
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
Envela Corporation (ELA) presents a stark dichotomy between explosive growth and deteriorating fundamental health. While the company exhibits hyper-growth in revenue (66.6%) and earnings (284.5%), the Piotroski F-Score of 3/9 indicates weak financial health and poor operational efficiency. The stock is currently trading at a premium ($18.50) relative to both its Graham Number ($5.70) and Intrinsic Value ($16.52), with a concerning Forward P/E (52.86) that exceeds its trailing P/E (33.04), suggesting a projected earnings slowdown.
The deterministic health profile is critical, highlighted by a weak Piotroski F-Score of 2/9 and a total lack of technical momentum (0/100). While the stock trades at a discount to book value (P/B 0.89), this is a classic value trap characterized by severe leverage (Debt/Equity 3.56) and poor liquidity (Current Ratio 0.73). Catastrophic YoY EPS growth (-1800%) and negative net profit margins indicate a business struggling to maintain solvency despite a high gross margin. The overall profile suggests a company in significant financial distress.
Compare Another Pair
Related Comparisons
ELA vs MSC: Head-to-Head Comparison
This page compares Envela Corporation (ELA) and Studio City International Holdings Limited (MSC) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.